DailyStocks Stock Article Search

https://www.zacks.com/commentary/2230125/top-analyst-reports-for-microsoft-amazon-com-berkshire-hathaway?cid=CS-ZC-FT-research_daily-2230125 Feb 22, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amazon.com, Inc. (AMZN) and Berkshire Hathaway Inc. (BRK.B). 0

https://www.zacks.com/stock/news/2239502/regeneron-regn-gets-fda-nod-for-praluent-label-extension?cid=CS-ZC-FT-analyst_blog|earnings_article-2239502 Mar 12, 2024 - Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH. 0

https://www.zacks.com/stock/news/2260438/sanofi-sny-rilzabrutinib-shows-benefit-in-blood-disorder-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2260438 Apr 23, 2024 - Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia. 0

https://www.zacks.com/stock/news/2262673/astrazeneca-azn-q1-earnings-sales-beat-estimates-stock-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2262673 Apr 25, 2024 - AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs. 0

https://www.zacks.com/stock/news/2239307/aslan-asln-up-161-on-upbeat-initial-data-from-eczema-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2239307 Mar 12, 2024 - ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response. 0

https://www.zacks.com/stock/news/2253429/nurix-nrix-up-on-upbeat-initial-data-from-phase-i-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253429 Apr 10, 2024 - Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies. 0

https://www.fool.com/earnings/call-transcripts/2024/04/25/sanofi-sny-q1-2024-earnings-call-transcript/?source=iedfolrf0000001 Apr 25, 2024 - SNY earnings call for the period ending March 31, 2024. 0